ESMO 2026 Takeaways: Data across 4 major trials de-risk c. $5bn in incremental sales for AZN's oncology franchise

At ESMO 2026, AstraZeneca presented four datasets in Presidential Symposia. DeLLphi-305 showed Imdelltra plus Imfinzi improved overall survival by 58% in first-line extensive-stage small cell lung cancer, de-risking a $1bn incremental opportunity for Imfinzi. CLARITY-Gastric01 showed a 53% overall survival benefit for Sone-V in third-line or later gastric cancer, de-risking a $2-3bn opportunity versus only $1.4bn of risk-adjusted consensus peak sales. VOLGA showed a 49% event-free survival benefit for Imfinzi plus Padcev given for only three cycles, offering similar efficacy with lower toxicity than Keytruda plus Padcev and supporting $1bn of Imfinzi sales in bladder cancer. SAFFRON showed a 32% overall survival improvement for Tagrisso plus Orpathys, de-risking a further $1bn of sales across the two brands. Overall, the data de-risk about $5bn of incremental sales for AstraZeneca's oncology franchise;